PreludeDx's Breakthrough Study Reveals DCISionRT® Enhances DCIS Treatment Decisions PreludeDx has unveiled new data showing that the DCISionRT® test outperforms traditional factors in assessing treatment for DCIS, guiding more effective patient care.

PreludeDx's Breakthrough Study Reveals DCISionRT® Enhances DCIS Treatment Decisions #Breast_Cancer #DCISionRT #PreludeDx

How Hannah Storm's Journey with DCIS and PreludeDx Amplifies Breast Cancer Awareness Hannah Storm teams up with PreludeDx, leveraging her story as a DCIS patient advocate to empower women through informed cancer treatment decisions.

How Hannah Storm's Journey with DCIS and PreludeDx Amplifies Breast Cancer Awareness #United_States #DCISionRT #PreludeDx #Laguna_Hills #Hannah_Storm

PreludeDx Secures FDA Breakthrough Device Status for DCISionRT® Test in Breast Cancer Management PreludeDx has announced that their DCISionRT® test for detecting the benefits of radiation therapy in DCIS breast cancer patients has received FDA Breakthrough Device designation, marking a significant advancement in patient care.

PreludeDx Secures FDA Breakthrough Device Status for DCISionRT® Test in Breast Cancer Management #United_States #FDA_Approval #DCISionRT #PreludeDx #Laguna_Hills